Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
13.16
0.39 (3.05%)
May 20, 2022 4:00 PM EDT - Market closed
Company Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 18 |
Contact Details
Address: 930 Winter Street Waltham, MA 02116 United States | |
| Phone | 617 443 2400 |
Stock Details
| Ticker Symbol | AVTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $14.00 |
| CIK Code | 1798749 |
Key Executives
| Name | Position |
|---|---|
| Timothy P. Noyes M.B.A. | Chief Executive Officer and Director |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer and Secretary |
| George A. Eldridge | Chief Financial Officer and Treasurer |
| Hunter Gillies M.D. | Chief Medical Officer |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Development Officer |
| Timothy J. Pigot | Senior Vice President of Commercial |
| Donna Dea | Head of Regulatory Affairs |
| Dr. Marinus Verwijs Ph.D. | Senior Vice President of CMC |
| Sue Fischer | Senior Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 16, 2022 | 8-K | Current report |
| May 5, 2022 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Apr 29, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2022 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2022 | 8-K | Current report |
| Apr 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 30, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Mar 30, 2022 | 8-K | Current report |
| View All SEC Filings | ||